Combination Therapies

Fixed-dose combinations and rational combinations improve outcomes across multiple therapeutic areas. The session covers the polypill in cardiovascular prevention (SECURE, PolyIran, WHO 2025), fixed-dose antiretroviral combinations (Biktarvy, Triumeq), combination immunotherapy (ipilimumab-nivolumab), MASH combination trials (resmetirom + GLP-1), and synergy assessment methodologies. Discussion addresses the regulatory pathway for combinations, the comparison of combination vs sequential vs alternation strategies, computational pharmacology in combination prediction, post-marketing combination data, and emerging triplet/quadruplet combinations.